Effect of short-term beta blockade on serum lipid levels and on the interaction of LDL with human arterial proteoglycans

• Published in: Journal of clinical pharmacology Vol. 30; no. S2; p. S124
• Main Authors: Lindén, T, Camejo, G, Wiklund, O, Warnold, I, Olofsson, S O, Bondjers, G
• Format: Journal Article
• Language: English
• Published: England 01.02.1990
• Subjects: Adult; Apolipoprotein A-I; Apolipoproteins - blood; Apolipoproteins A - blood; Atenolol - blood; Cholesterol - blood; Cholesterol, HDL - blood; Delayed-Action Preparations; Female; Humans; Isoelectric Focusing; Lipids - blood; Lipoproteins, LDL - blood; Male; Metoprolol - administration & dosage; Metoprolol - pharmacology; Middle Aged; Proteoglycans - blood; Triglycerides - blood
• DOI: 10.1002/j.1552-4604.1990.tb03510.x
• ISSN: 0091-2700

In view of conflicting evidence suggesting that beta-blockers have an anti-atherogenic effect as well as induce a potentially atherogenic lipoprotein profile, the effects of a short term beta-blockade on serum lipoproteins were studied in 39 healthy volunteers. Because the interaction of LDL with arterial proteoglycans appears to play a role in lipoprotein accumulation during atherogenesis, the effects of metoprolol and atenolol on low density lipoprotein interaction with human aortic proteoglycans were included in the study. We could confirm that the beta-blockers caused a decrease in HDL cholesterol and an increase in triglycerides, both potentially undesirable effects. In addition, however they induced a significant decrease in the in vitro LDL affinity for arterial proteoglycans. Since there appears to be a strong association between LDL reactivity with proteoglycans and risk for myocardial infarction, this effect of the beta-blockers may be an anti-atherogenic effect which overrides other effects on the lipoprotein pattern.